For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Medarex Inc.

USPTO Granted Patents = 152

% Expired Patents = 28.3

CIPO Patents = 17

EPO Patents = 30

Forward Citations = 6,363

Loading Chart...

Loading Chart...

200 inventors (with patents filed for the assignee):

Sanjeev Gangwar (26 out of 73 patents)

Haichun Huang (23 out of 82 patents)

Josephine M Cardarelli (21 out of 43 patents)

4. Alan J Korman (20 out of 88 patents)

5. David J King (16 out of 54 patents)

6. Robert F Graziano (16 out of 23 patents)

7. David B Passmore (15 out of 25 patents)

8. Tibor P Keler (15 out of 40 patents)

9. Nils Lonberg (14 out of 68 patents)

10. Mohan Srinivasan (14 out of 78 patents)

11. Yashwant M Deo (14 out of 21 patents)

12. Edward L Halk (13 out of 28 patents)

13. Alison Witte (13 out of 26 patents)

14. Lesley B Pickford (12 out of 12 patents)

15. Israel Lowy (11 out of 33 patents)

Core Competencies:

Monoclonal Antibodies

CTLA-4

PD-1

Anti-B7RP1

Therapeutic Antibodies

Cancer Treatment

Interferon Alpha

Chimeric Antibodies

Antibody-Drug Conjugates

Transgenic Animals

Antibody Engineering

Immunotherapy

152 patents: Sort by Forward Citations

1. 10072090 - Human anti-B7RP1 neutralizing antibodies (2018-09-11),

2. 9062111 - CTLA-4 antibody dosage escalation regimens (2015-06-23),

3. 8981071 - Human anti-B7RP1 neutralizing antibodies (2015-03-17),

4. 8945546 - IP-10 antibodies and their uses (2015-02-03),

5. 8865875 - Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions (2014-10-21),

6. 8835712 - Transgenic trasnchromosomal rodents for making human antibodies (2014-09-16),

7. 8828393 - Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist (2014-09-09),

8. 8802632 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof (2014-08-12),

9. 8784815 - Human CTLA-4 antibodies and their uses (2014-07-22),

10. 8779105 - Monoclonal antibodies to programmed death 1 (PD-1) (2014-07-15),

11. 8772543 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof (2014-07-08),

12. 8772542 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof (2014-07-08),

13. 8765415 - Methods for enhanced protein production (2014-07-01),

14. 8758757 - Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) (2014-06-24),

15. 8722870 - Nucleic acids encoding interferon alpha antibodies (2014-05-13),

Company Overview

Medarex Inc., based in Princeton, NJ, specializes in the development of monoclonal antibodies for therapeutic applications, particularly in cancer treatment. The company focuses on innovative technologies targeting immune checkpoints such as CTLA-4 and PD-1, as well as anti-B7RP1 and interferon alpha. Medarex is dedicated to advancing therapeutic antibodies and chimeric antibodies, contributing to the evolving landscape of immunotherapy and enhancing treatment options for patients with various malignancies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

152 Patents

#14 in Princeton, NJ

#123 in New Jersey

#2,599 in US

#5,376 in the World

Princeton, NJ, United States of America

Medarex Inc.

Forward Citations = 6,363

200 inventors:

Sanjeev Gangwar (26 out of 73 patents)

Haichun Huang (23 out of 82 patents)

Josephine M Cardarelli (21 out of 43 patents)

4. Alan J Korman (20 out of 88 patents)

5. David J King (16 out of 54 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medarex Inc.. Retrieved from https://idiyas.com/company/medarex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…